Lauren Biscaldi

Last week, the US Food and Drug Administration approved biosimilar ustekinumab-aekn (Selarsdi; Alvotech and Teva) for psoriasis and PsA.

In January 2023, adalimumab-atto became the first biosimilar product available for the reference product adalimumab.

The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.

The current dermatology pipeline includes a wide range of medication classes, from Janus kinase (JAK) inhibitors to tumor necrosis factor inhibitors, to phototherapeutics

Patient adherence to self-management strategies can be difficult.

New pathways of care are needed to improve health care spending.

CBD therapy has had positive outcomes in other inflammatory conditions.

The decision comes following reports of 16,000 cases across 75 countries and territories around the world.